1. |
赵江峰, 叶霜. 抗mda5抗体相关皮肌炎的诊疗进展. 中华检验医学杂志, 2021, 44(11): 1070-1075.
|
2. |
McPherson M, Economidou S, Liampas A, et al. Management of MDA-5 antibody positive clinically amyopathic dermatomyositis associated interstitial lung disease: a systematic review. Semin Arthritis Rheum, 2022, 53: 151959.
|
3. |
Lundberg IE, Tjärnlund A, Bottai M, et al. 2017 European League against Rheumatism/American College of Rheumatology Classification Criteria for Adult and Juvenile Idiopathic Inflammatory Myopathies and their Major Subgroups. Ann Rheum Dis, 2017, 76(12): 1955-1964.
|
4. |
Travis WD, Costabel U, Hansell IIM, et al. An official American Thoracic Society European Respiratory Society Statement: Update of the International Multidisciplinary Classification of the Idiopathic Interstitial Pneumonias. Am J Respir Crit Care Med, 2013, 188(6): 733-748.
|
5. |
Xu Y, Yang CS, Li YJ, et al. Predictive factors of rapidly progressive-interstitial lung disease in patients with clinically amyopathic dermatomyositis. Clin Rheumatol, 2016, 35(1): 113-116.
|
6. |
武雅楠, 王颖嫒, 祁福敏, 等. 抗黑色素瘤分化相关蛋白-5抗体阳性炎性肌病临床特征分析. 中华风湿病学杂志, 2022, 26(2): 105-114.
|
7. |
马文兰, 白灵, 朱嘉睿, 等. 抗黑色素瘤分化相关基因5抗体阳性皮肌炎合并间质性肺病的发病机制研究进展. 中华风湿病学杂志, 2021, 25(12): 841-845.
|
8. |
Kurtzman D, Vleugels RA. Anti-melanoma differentiation associated gene5 (MDA5) dermatomyositis aconcise review with an emphasis on distinctive clinical features. Am Acad Dermatol, 2018, 78 (4): 776-785.
|
9. |
Allenbach Y, Uzunhan Y, Toquet S, et al. Different phenotypes in dermatomyositis associated with anti-MDA5 antibody: study of 121 cases. Neurology, 2020, 95(1): e70-e78.
|
10. |
Gono T, Kawaguchi Y, Satoh T, et al. Clinical manifestation and prognostic factor in anti-melanoma differentiation-associated gene 5 antibody-associated interstitial lung disease as a complication of dermatomyositis. Rheumatology (Oxford), 2010, 49(9): 1713-1719.
|
11. |
Moghadam-Kia S, Oddis CV, S ato S, et al. Anti-me1anoma differentiation-associated gene 5 is associated with rapidly progressive lung disease and poor survival in US patients with amyopathic and myopathic dermatomyositis. Arthritis Care Res, 2016, 68(5): 689-694.
|
12. |
Tsuji H, Nakashima R, Hosono Y, et al. Multicenter prospective study of the efficacy and safety of combined immunosuppressive therapy with high-dose glucocorticoid, tacrolimus, and cyclophosphamide in interstitial lung diseases accompanied by anti-melanoma differentiation-associated gene 5-positive dermatomyositis. Arthritis Rheumatol, 2020, 72(3): 488-498.
|
13. |
Chen ZW, Wang XD, Ye S. Tofacitinib in amyopathic dermatomyositis-associated interstitial lung disease. N Engl J Med, 2019, 381(3): 291-293.
|
14. |
康宁, 陈鸿志, 周永慧, 等. 联用托法替布成功治疗MDA5阳性无肌炎型皮肌炎相关间质性肺病一例. 中国呼吸与危重监护杂志, 2021, 20(6): 440-443.
|
15. |
Ge YP, Li SS, Tian XL, et al. Anti-melanoma differentiation-associated gene 5 (MDA5) antibody-positive dermatomyositis responds to rituximab therapy. Clin Rheumatol, 2021, 40(6): 2311–2317.
|
16. |
Shirakashi M, Nakashima R, Tsuji H, et al. Efficacy of plasma exchange in anti-MDA5-positive dermatomyositis with interstitial lung disease under combined immunosuppressive treatment. Rheumatology, 2020, 59(11): 3284–3292.
|
17. |
鞠伟威, 王培绒, 杨国欢, 等. 抗MDA-5抗体阳性炎性肌病合并间质性肺病的临床特点和预后分析. 国际呼吸杂志, 2022, 42(4): 267-274.
|
18. |
Lian XY, Zou J, Guo Q, et al. Mortality risk prediction in amyopathic dermatomyositis associated with interstitial lung disease: the FLAIR model. Chest, 2020, 158(4): 1535-1545.
|
19. |
Habe K, Wada H, Higashiyama A, et al. Elevated plasma D-dimer levels in dermatomyositis patients with cutaneous manifestations. Sci Rep, 2019, 9(1): 1410.
|
20. |
徐婷, 张光峰, 林浩博, 等. 抗黑色素瘤分化相关基因5抗体阳性皮肌炎合并快速进展性间质性肺病的临床及预后分析. 中华风湿病学杂志, 2021, 25(6): 361-367.
|
21. |
Sabbagh S, Pinal-Fernandez I, Kishi T, et al. Anti-Ro52 auto-antibodies are associated with interstitial lung disease and more severe disease in patients with juvenile myositis. Ann Rheum Dis, 2019, 78(7): 988-995.
|
22. |
Temmoku J, Sato S, Fujita Y, et al. Clinical significance of myositis-specific auto antibody profiles in Japanese patients with polymyositis/dermatomyositis. Medicine, 2019, 98(20): e15578.
|
23. |
Ye Y, Fu Q, Wang R, et al. Serum KL-6 level is a prognostic marker in patients with anti-MDA5 antibody-positive dermatomyositis associated with interstitial lung disease. J Clin Lab Anal, 2019, 33(8): e22978.
|
24. |
Li YH, Li YM, Wu J, et al. Predictors of poor outcome of anti-MDA5-associated rapidly progressive interstitial lung disease in a Chinese cohort with dermatomyositis. J Immunol Res, 2020, 2020: 2024869.
|
25. |
陈望, 高万勤, 史晓飞, 等. 抗黑色素瘤分化相关基因5抗体阳性皮肌炎的临床和胸部CT表现. 中华放射学杂志, 2021, 55(2): 143-147.
|
26. |
Egashira R. High-resolution CT findings of myositis-related interstitial lung disease. Medicina (Kaunas), 2021, 57(7): 692.
|